Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C7H6ClN3O4S2.ClH |
| Molecular Weight | 332.184 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NS(=O)(=O)C1=C(Cl)C=C2N=CNS(=O)(=O)C2=C1
InChI
InChIKey=GQWPZOKTQKQAPN-UHFFFAOYSA-N
InChI=1S/C7H6ClN3O4S2.ClH/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5;/h1-3H,(H,10,11)(H2,9,12,13);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C7H6ClN3O4S2 |
| Molecular Weight | 295.723 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00880Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/diuril-injection.html
Sources: http://www.drugbank.ca/drugs/DB00880
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/diuril-injection.html
Like other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na /Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. As a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. It is marketed under the brand name Diuril.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13802826
Curator's Comment: Chlorothiazide was synthesized by Novello and Sprague in 1957
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL261 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL205 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL3729 Sources: http://www.drugbank.ca/drugs/DB00880 |
|||
Target ID: CHEMBL1876 Sources: http://www.drugbank.ca/drugs/DB00880 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Diuril Approved UseIntravenous Sodium DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Intravenous Sodium DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Launch Date1958 |
|||
| Primary | Diuril Approved UseIntravenous Sodium DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy.
Intravenous Sodium DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Launch Date1958 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
90 min |
unknown |
CHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
60% |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
CHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Hypersensitivity, Azotemia... AEs leading to discontinuation/dose reduction: Hypersensitivity Sources: Azotemia Systemic lupus erythematosus reactivation |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Azotemia | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Hypersensitivity | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
| Systemic lupus erythematosus reactivation | Disc. AE | 1000 mg 2 times / day multiple, oral Recommended Dose: 1000 mg, 2 times / day Route: oral Route: multiple Dose: 1000 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Page: abstract |
no | |||
Page: abstract |
no | |||
Page: abstract |
weak [IC50 2205 uM] | |||
Page: abstract |
weak [IC50 2632 uM] | |||
Page: 9.0 |
yes [IC50 212 uM] | |||
Page: abstract |
yes [IC50 3.78 uM] | |||
Page: abstract |
yes [IC50 65.3 uM] |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| no | ||||
| no | ||||
| no | ||||
| no | ||||
Page: 3.0 |
yes | |||
Page: S34 |
yes | |||
Page: S34 |
yes |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015-05-18 |
|
| Transparotid approach for mandibular condylar neck and subcondylar fractures. | 2010-12 |
|
| Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort. | 2010-10 |
|
| Impacts of intensive agricultural irrigation and livestock farming on a semi-arid Mediterranean catchment. | 2010-08 |
|
| Speeding up the process urine sample pre-treatment: some perspectives on the use of microwave assisted extraction in the anti-doping field. | 2010-06-15 |
|
| Thiazide-induced hyponatremia. | 2010-06 |
|
| Surgical anatomy of the lower eyelid relating to lower blepharoplasty. | 2010-03 |
|
| Running away experience and psychoactive substance use among adolescents in Taiwan: multi-city street outreach survey. | 2010-01-20 |
|
| Formulation optimization of hydrodynamically balanced oral controlled release bioadhesive tablets of tramadol hydrochloride. | 2010-01-06 |
|
| Buccal fat pad versus sandwich graft for treatment of oroantral defects: A comparison. | 2010-01 |
|
| Expression of therapeutic misconception amongst Egyptians: a qualitative pilot study. | 2009-06-30 |
|
| Do new drugs increase life expectancy? A critique of a Manhattan Institute paper. | 2009-05 |
|
| Healing virtue: Saludadores versus witches in early modern Spain. | 2009 |
|
| Fast gas chromatographic/mass spectrometric determination of diuretics and masking agents in human urine: Development and validation of a productive screening protocol for antidoping analysis. | 2006-12-01 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| Thiazide diuretics and the risk of gallbladder disease requiring surgery in women. | 2005-03-14 |
|
| Releasing the flood waters: diuril and the reshaping of hypertension. | 2005 |
|
| Hyperinsulinism in tyrosinaemia type I. | 2005 |
|
| Electrochemical behavior of the antituberculosis drug isoniazid and its square-wave adsorptive stripping voltammetric estimation in bulk form, tablets and biological fluids at a mercury electrode. | 2003-11-24 |
|
| Are certain diuretics also anticonvulsants? | 2001-10 |
|
| Thiazide therapy for ACTH-induced hypercalciuria and nephrolithiasis. | 1992-03 |
|
| Milk-alkali syndrome associated with use of chlorothiazide and calcium carbonate. | 1989-03 |
|
| Diuretic-associated pancreatitis: a collective review and illustrative cases. | 1987-09 |
|
| Thiazide-induced hyponatremia. | 1983-11 |
|
| Reversal of vitamin-D2-induced hypercalciuria by chlorothiazide. | 1983-02 |
|
| Renal calcifications: a complication of long-term furosemide therapy in preterm infants. | 1982-09 |
|
| Cimetidine and visual hallucinations. | 1978-07-21 |
|
| Hyperosmolality complicating recovery from lithium toxicity. | 1978-06-10 |
|
| On the mechanism of lithium-induced diabetes insipidus in man and the rat. | 1974-04 |
|
| Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. | 1973-09 |
|
| Chlorothiazide-induced hypercalcemia in juvenile osteoporosis and hyperparathyroidism. | 1969-07-10 |
|
| Iliacus haematoma syndrome as a complication of anticoagulant therapy. | 1968-10-12 |
|
| Toxic effects of a chlorothiazide-diazoxide combination on adipose tissue and kidneys of intact rats. | 1968-06 |
|
| Metabolic and hormonal studies in a patient with primary aldosteronism, presenting with acute hypokalaemic paresis induced by chlorothiazide. | 1968-05 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/diuril-injection.html
The usual adult dosage is 0.5 to 1 g once or twice a day.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8914012
Chlorothiazide (1000 uM) inhibited osteocalcin secretion (-42 +/- 12.7%) in human model cell line MG-63
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:07:41 GMT 2025
by
admin
on
Wed Apr 02 11:07:41 GMT 2025
|
| Record UNII |
JCS5G4J7AC
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
17278-61-4
Created by
admin on Wed Apr 02 11:07:41 GMT 2025 , Edited by admin on Wed Apr 02 11:07:41 GMT 2025
|
PRIMARY | |||
|
129846846
Created by
admin on Wed Apr 02 11:07:41 GMT 2025 , Edited by admin on Wed Apr 02 11:07:41 GMT 2025
|
PRIMARY | |||
|
JCS5G4J7AC
Created by
admin on Wed Apr 02 11:07:41 GMT 2025 , Edited by admin on Wed Apr 02 11:07:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|